Dynavax Technologies CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
10-K: Dynavax Technologies Reports Strong HEPLISAV-B Sales Growth in 2024, Advances Vaccine Pipeline
Dynavax Technologies reports a 26% increase in HEPLISAV-B product revenue for 2024, driven by market expansion and market share gains, while also advancing its shingles and plague vaccine programs.
Dynavax Technologies Corp. saw a 69% increase in HEPLISAV-B revenue in 2023 and is progressing its shingles, Tdap, and plague vaccine programs.